首页 > 市场调查报告书 > 製药

开发平台分析

市场调查报告书

商品编码

1358056

组织纤溶酶原激活剂市场：依药物类型、依用途、按地区

Tissue Plasminogen Activator Market, By Drug Type, By Application, By Geography

出版日期: 2023年09月20日 | 出版商:

Coherent Market Insights | 英文 141 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年，全球组织纤溶酶原激活剂市场估计为25.8亿美元，预计在预测期内（2023-2030年）年复合成长率为5.2%。

报告范围		报告详情
基准年	2022年	2023年市场规模	25.8亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	5.20%	2030年市场规模预测	36.8亿美元

组织纤溶酶原激活剂全球市场占有率(%)，依药物类型，2023 年

组织纤溶酶原激活剂，也称为组织型纤溶酶原激活剂(tPA)，是一种存在于内皮细胞（动脉内壁细胞）中的丝氨酸蛋白酶，参与分解血栓（纤维蛋白溶解）的过程。纤溶酶原经由 tPA 酶转化为纤溶酶。 tPA 用于栓塞和血栓性中风研究。

tPA 可以使用重组生物技术生产。这种类型的 tPA 称为重组组织纤溶酶原激活剂 (rtPA)。 t-PA 是一种存在于血液和组织中的蛋白水解酶。 t-PA 的主要生理功能是产生纤溶酶，从而破坏脉管系统中的血栓。

市场动态

由于组织纤溶酶原激活剂（tPA）用于治疗缺血性中风，缺血性中风患病的增加预计将推动自由铸造期的市场成长。例如，根据世界中风组织 (WSO) 的数据，到 2022 年，全球每年将新增超过 760 万例缺血性中风。 2019年，缺血性中风占全球中风的62%以上。近 11% 的缺血性中风发生在 15 至 49 岁的人群中。

此外，根据美国心臟协会 2022 年报告，2020 年全球约有 2.441 亿人患有缺血性心臟疾病(IHD)。这种疾病在男性中更为常见，罹患约 1.41 亿人，而女性估计为 1.031 亿人。

本研究的主要特点

本报告对全球组织纤溶酶原激活剂市场进行了详细分析，并提出了以2022年为基准年的预测期（2023-2030）的市场规模和年复合成长率(CAGR)。
它还阐明了各个细分市场的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
它还提供了有关市场促进因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
它根据公司亮点、产品系列、主要亮点、绩效和策略等参数，介绍了全球组织纤溶酶原激活剂市场的主要企业。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、类型升级、市场经营团队和行销策略做出明智的资讯。
全球组织纤溶酶原激活剂市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
透过用于分析全球组织纤溶酶原激活剂市场的各种策略矩阵，将促进相关人员的决策。

Report Coverage	Report Details
Base Year:	2022	Market Size in 2023:	US$ 2.58 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	5.20%	2030 Value Projection:	US$ 3.68 Bn

Tissue plasminogen activator, also known as tissue-type plasminogen activator (tPA), is a serine protease that is present in endothelial cells, the cells that line blood arteries, and is involved in the process of breaking down blood clots (fibrinolysis). Plasminogen is transformed into plasmin by the tPA enzyme. tPA can be employed in studies on embolic or thrombotic stroke.

tPA may be produced by using recombinant biotechnology methods. This kind of tPA is known as recombinant tissue plasminogen activator (rtPA). t-PA is a proteolytic enzyme present in blood and tissues. The primary physiological function of t-PA is the production of plasmin that can break blood clots in the vasculature.

Market Dynamics

Increasing prevalence of ischemic stroke is expected to drive the market growth over frecast period as tissue-type plasminogen activator (tPA) is used to treat ischemic stroke. For instance, in 2022, according to World Stroke Organization (WSO), there are over 7.6 million new ischemic strokes each year worlwide. Ischemic strokes accounted for more than 62% of incident strokes worldwide in 2019. People aged 15 to 49 account for nearly 11% of all ischemic strokes each year.

Moreover, according to the 2022 report from the American Heart Association, there were approximately 244.1 million individuals globally living with ischemic heart disease (IHD) in the year 2020. This condition was found to be more prevalent among males, with approximately 141.0 million affected, compared to females, where the estimated number of affected individuals was 103.1 million.

Key features of the study:

This report provides an in-depth analysis of the global tissue plasminogen activator market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global tissue plasminogen activator market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, CHIESI Farmaceutici S.p.A., Gennova Biopharmaceuticals Ltd, Abbott Laboratories, and Reliance Life Sciences
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global tissue plasminogen activator market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tissue plasminogen activator market

Detailed Segmentation:

By Drug Type:
- Alteplase
- Reteplase
- Tenecteplase
By Application:
- Ischemic Stroke
- Myocardial Infarction
- Pulmonary Embolism
- Thrombolysis
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles
- F. Hoffmann-La Roche AG.
- Boehringer Ingelheim GmbH
- CHIESI Farmaceutici S.p.A.
- Gennova Biopharmaceuticals Ltd
- Abbott Laboratories
- Reliance Life Sciences

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Application
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trend
Epidemiology
Key Developments
Regulatory Scenario
PEST Analysis
Pipeline Analysis
Acquisition and Collaboration Scenario

4. Global Tissue Plasminogen Activator Market- COVID-19 Impact Analysis

COVID-19 Epidemiology
Overall Impact on Healthcare Sector
Total Impact of COVID-19 on Global Tissue Plasminogen Activator Market
Government Recommendations

5. Global Tissue Plasminogen Activator Market, By Drug Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Alteplase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030, (US$ Bn)
- Segment Trends
Reteplase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Tenecteplase
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

6. Global Tissue Plasminogen Activator Market, By Application, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
Ischemic Stroke
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Myocardial Infarction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Pulmonary Embolism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Thrombolysis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

7. Global Tissue Plasminogen Activator Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
- U.S.
- Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018 -2030, (US$ Bn)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Heat Map Analysis
Company Profiles
- F. Hoffmann-La Roche AG
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Boehringer Ingelheim GmbH
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- CHIESI Farmaceutici S.p.A.
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Gennova Biopharmaceuticals Ltd
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Abbott Laboratories
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Reliance Life Sciences
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies

9. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

组织纤溶酶原激活剂市场：依药物类型、依用途、按地区

Tissue Plasminogen Activator Market, By Drug Type, By Application, By Geography

市场动态

目录

第1章调查目的和假设

第2章市场展望

第3章市场动态、法规及趋势分析

第4章全球组织纤溶酶原激活剂市场 - COVID-19 疾病的影响分析

第5章全球组织纤溶酶原激活剂市场，依药物类型，2018-2030

第6章全球组织纤溶酶原激活剂市场，依用途，2018-2030

第7章全球组织纤溶酶原激活剂市场，按地区，2018-2030

第8章竞争形势

第9章章节